GenPath and Merck & Co sign oncology deal
GenPath Pharmaceuticals has signed a collaborative agreement with drugmajor Merck & Co in the field of oncology, under which the former will utilize its proprietary cancer models to identify essential tumor maintenance genes which may provide targets for the development of small-molecule drugs.
Under the terms of the deal, Merck will have an exclusive option to license the worldwide rights to a specific number of targets discovered and validated by GenPath and will be responsible for the development and commercialization of any products arising from the collaboration.
In return, GenPath will receive an upfront payment and annual research funding. Furthermore, the company will be entitled to milestones and royalties based on product sales. The deal could provide GenPath with total payments in excess of $100 million.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze